Date: 2011-11-07
Type of information: Development agreement
Compound: pancreatic cancer specific biomarkers
Company: Oxford Gene Technology (UK) Abcodia (UK)
Therapeutic area: Cancer - Oncology
Type agreement: development
collaboration
Action mechanism:
Disease: pancreatic cancer
Details: * On November 7, 2011, Oxford Gene Technology (OGT), a UK provider of genetics and biomarker solutions to advance molecular medicine, has announced a collaborative agreement with Abcodia aimed at improving the early detection of pancreatic cancer. As part of this collaboration, Abcodia will provide access to its large prospective serum biobank, to harness samples taken from individuals up to 7 years before the diagnosis of pancreatic cancer. OGT will apply its functional protein array platform and its Genefficiency™ microRNA profiling array to identify pancreatic cancer specific biomarkers that can be used as diagnostic indicators of developing pancreatic cancer. Both OGT and Abcodia will bring their expertise in experimental design and analysis.
Financial terms: Financial details of the partnership were not disclosed.
Latest news:
